70720-125 : Xermelo 250 mg Oral Tablet
NDC: | 70720-125 |
Labeler: | Tersera Therapeutics LLC |
Product Type: | Human Prescription Drug |
Drug Name: | Xermelo |
Dosage Form: | Oral Tablet |
Application #: | NDA208794 |
Rev. Date: |
NDC Package Codes:
- 70720-125-85: 4 BOX IN 1 CASE (70720‑125‑85) > 1 BLISTER PACK IN 1 BOX (70720‑125‑22) > 21 TABLET IN 1 BLISTER PACK
Active Ingredients:
- Telotristat Ethyl
Dosage Strength:
- 250 mg
Pharmaceutical Classes:
- Tryptophan Hydroxylase Inhibitor [EPC]
- Tryptophan Hydroxylase Inhibitors [MoA]
Related Products:
Based on records with the same trade name.- 70183-125 Xermelo 250 mg Oral Tablet by Lexicon Pharmaceuticals, Inc.
NDC QR Code
Scan the QR code below to easily reference this data in the future:< Prev: 70720-120Next: 70720-175 >
Related Discussions:
eryth ethylsuc tab
infection ## Have been taking 3 times a day for 5 days. Bowels are loose and stomach feels like bathroom almost constant... 2 replies
infection ## Have been taking 3 times a day for 5 days. Bowels are loose and stomach feels like bathroom almost constant... 2 replies
eryth ethylsuc
pink capsule 74 ze ## I located your pill to be Erythromycin ethylsuccinate (400 mg). Erythromycin is a macrolide antibi... 1 reply
pink capsule 74 ze ## I located your pill to be Erythromycin ethylsuccinate (400 mg). Erythromycin is a macrolide antibi... 1 reply
ERYTHROMYCIN ETHYL 400MG
REASON PRESCRIBED ## Erythromycin is an antibiotic. It's used to treat many kinds of infection. (including pneumonia... 3 replies
REASON PRESCRIBED ## Erythromycin is an antibiotic. It's used to treat many kinds of infection. (including pneumonia... 3 replies
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.